Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.43 USD | -0.91% | +5.23% | -57.41% |
May. 29 | Treace Medical Concepts Insider Bought Shares Worth $253,475, According to a Recent SEC Filing | MT |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-57.41% | 340M | C- | ||
+75.69% | 12.57B | B- | ||
-24.12% | 7.29B | C+ | ||
+10.90% | 6.81B | C- | ||
+20.88% | 5.67B | D+ | ||
-16.83% | 4.91B | B | ||
+19.43% | 4.18B | - | ||
-21.23% | 3.86B | B- | ||
-24.00% | 2.92B | C | ||
+52.88% | 2.57B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TMCI Stock
- Ratings Treace Medical Concepts, Inc.